ArticleInfectious agents and cancer2025
Exploratory analysis of lamivudine legacy and clonal selection of HBs truncation mutants in HBV-related hepatocellular carcinoma.
Article in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hepatitis B virus (HBV) integration and persistent covalently closed circular DNA (cccDNA) are key drivers of hepatocarcinogenesis and remain uncured by current nucleos(t)ide analog (NA) therapy. While high-barrier NAs like entecavir effectively suppress viral replication, they do not eliminate transcriptionally active HBV integrants. In this exploratory study, we analyzed HBV surface (HBs) gene truncation mutations in four patients with HBV-related hepatocellular carcinoma (HCC), including two with prior lamivudine exposure. Next-generation sequencing of DNA and RNA from serum, tumor, and para-neoplastic liver tissues revealed truncation variants, such as sW172* and sW182* were, exclusively in the two lamivudine-experienced patients. These variants were predominantly enriched in tumor RNA, raising the possibility of clonal selection during hepatocarcinogenesis. No truncation mutations were observed in the two patients treated solely with entecavir, despite detectable intrahepatic cccDNA. These findings support the hypothesis that transcriptionally active HBV integrants, possibly shaped by prior lamivudine treatment, may contribute to HCC via truncated HBs protein expression. The selective presence of certain mutants in tumor tissue suggests a potential biological role, though further validation is needed. Given the small sample size and limited number of lamivudine-experienced cases, our observations should be interpreted with caution. Nevertheless, the results highlight the relevance of antiviral treatment history in shaping HBV mutational profiles and raise the possibility that integrant-derived HBs truncation variants could serve as biomarkers for HCC risk stratification. Early detection of such variants may help refine surveillance strategies in virally suppressed patients and inform future therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.